Monday, 16 November 2015

Global Non-Small Cell Lung Cancer Treatment Market Value to Approach $11 Billion by 2021, says GBI Research

The global market value for Non-Small Cell Lung Cancer (NSCLC) treatment will rise from $6.9 billion in 2014 to $10.9 billion by 2021, representing a Compound Annual Growth Rate (CAGR) of 8.5%, says business intelligence provider GBI Research.

The company’s latest report states that this increase will occur across the eight major markets of the US, Canada, UK, Germany, France, Italy, Spain and Japan, driven primarily by the introduction of novel immune-checkpoint inhibitors, such as Opdivo and Keytruda, during the forecast period.

These new therapies will capture a significant share of the second-line treatment space. As well as strong clinical performances commanding premium pricing, they are expected to increase the degree of segmentation in the NSCLC therapeutics market and add further complexity to the treatment algorithm.

Joshua Libberton, Senior Analyst for GBI Research, says: “The majority of new drugs will target the second-line treatment of NSCLC in both squamous and non-squamous patient subsets, leading to a crowded treatment algorithm for these patient populations.

“Ultimately, due to their strong clinical performances, immunotherapies will have a greater uptake than other second-line market entrants, such as Custirsen and Rociletinib.”

The analyst adds that the NSCLC therapeutics market will also see the launches of two first-line treatments for squamous cell patients during the forecast period, namely Necitumumab, which is due to launch in early 2016, and Yervoy (ipilimumab) in 2017.

“While generic chemotherapies will remain an integral aspect of NSCLC treatment, with platinum-based regimens being crucial in the first-line setting for all patients and docetaxel being a key therapy for second-line patients, their market share will slowly decline by 2021 as new premium, targeted therapies enter the arena.”

This report provides analysis on the non-small cell lung cancer therapeutics market across the eight major markets of the US, Canada, UK, Germany, France, Italy, Spain and Japan, from 2014 and forecast to 2021.

This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GBI Research’s team of industry experts.

Reasons to buy
This report will allow you to;

- Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies.
- Visualize the composition of the NSCLC market in terms of dominant therapies for each patient subset along with their clinical and commercial standing. Unmet needs in the current market are highlighted to allow a competitive understanding of gaps in the current market.
- Analyse the NSCLC pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target.
- Understand the potential of late-stage therapies with extensive profiles of products that could enter the market over the forecast, highlighting clinical performance, potential commercial positioning, and how they will compete with other therapies.
- Predict NSCLC market growth in eight major markets with epidemiological and ACoT forecasts across the US, Canada, UK, France, Germany, Italy, Spain and Japan, as well as individual drug contributions to market growth.
- Identify commercial opportunities in the NSCLC deals landscape by analysing trends in licensing and co-development deals.


For Discount Coupon click here

For any queries reach us

Reach us:

Sam Collins
Market Reports Center
1-646-883-3044 (US)
+91- 20-41217796 (IND)

No comments:

Post a Comment